TSEN54 Inhibitors

Chemical inhibition of TSEN54 functions involves targeting related pathways and complexes due to the non-catalytic nature of TSEN54. The primary approach is to affect the broader RNA splicing and processing machinery, which indirectly impacts TSEN54's role in the tRNA-splicing endonuclease complex. The inhibitors listed above primarily target various components of the spliceosome, a crucial complex for pre-mRNA splicing. By inhibiting these components, the chemical agents alter the processing of both mRNA and tRNA, thereby indirectly affecting the function of TSEN54. The spliceosome, comprising numerous small nuclear ribonucleoproteins (snRNPs) and various other associated proteins, is essential for the removal of introns from pre-mRNA. Inhibitors like Pladienolide B, Spliceostatin A, and Meayamycin exert their effects by binding to the SF3b complex, a subunit of the spliceosome, thus altering splicing fidelity and dynamics. This alteration can ripple through to the tRNA splicing process, in which TSEN54 plays a structural and regulatory role. Similarly, compounds like E7107 and H3B-8800, which target other aspects of the spliceosome, can indirectly influence the operational environment of TSEN54.

Additionally, inhibitors that affect general RNA processing and translation, like Plitidepsin and Chloroquine, can create a cellular context where the function of TSEN54 in RNA processing might be altered. These chemicals do not target TSEN54 directly but modulate the cellular processes in which TSEN54 is involved. This indirect approach to inhibition is pivotal in the context of non-catalytic proteins like TSEN54, where direct enzymatic activity is not the primary functional characteristic. The overall impact of these inhibitors suggests a broader understanding of the interplay between mRNA processing, tRNA splicing, and the functionalities of non-catalytic subunits within these critical biochemical pathways.